FDA rejects Novartis' biosim app for Amgen blockbuster - FierceBiotech

FierceBiotech

FDA rejects Novartis' biosim app for Amgen blockbuster FierceBiotech Buried deep down in Novartis' ($NVS) Q2 results out this morning was a previously unknown rejection by the FDA for a copycat version of Amgen's ($AMGN) blockbuster drug Neulasta (pegfilgrastim). The biosimilar, coming out of its Sandoz unit, was ... US FDA knocks back Novartis copy of Amgen's drug NeulastaReuters all 2 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEeE5nUFsSuvu8nd2QpiosQVnH5lA&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779163030774&ei=qCuOV9jQIdC33gHurbrIDw&url=http://www.fiercebiotech.com/biotech/fda-rejects-novartis-biosim-app-for-amgen-blockbuster
via IFTTT